FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cette étude analyse les données de l'essai non randomisé ayant conduit la "Food and Drug Administration" à autoriser l'utilisation du mobocertinib pour traiter les patients atteints d'un cancer du poumon non à petites cellules de stade localement avancé ou métastatique et présentant des mutations de l'EGFR par insertion de l'exon 20
On September 15, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals USA, Inc.) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. The approval was based on data from Study AP32788-15-101 (NCT02716116), an international, non-randomized, multi-cohort clinical trial which included patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The overall response rate (ORR) in 114 patients whose disease had progressed on or after platinum-based chemotherapy was 28% (95% CI: 20%, 37%) with a median duration of response of 17.5 months (95% CI: 7.4, 20.3). The most common adverse reactions (>20%) were diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain. Product labeling includes a Boxed Warning for QTc prolongation and Torsades de Pointes. This is the first approval of an oral targeted therapy for patients with advanced EGFR exon 20 insertion mutation-positive NSCLC.